References
- Allanson, JE, Roberts AE. Noonan syndrome. Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK1124/ 2019, August 8.
- Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome.Lancet. 2013; 381: 333-42.
- Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical
features, diagnosis, and management guidelines. Pediatrics.2010; 126: 746-59.
- Noonan JA, Ehmke DA. Associated noncardiac malformations in children
with congenital heart disease. Midwest Soc Pediatr Res. 1963;
63: 468-70.
- Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet.1985; 21: 493-506.
- Tartaglia M, Gelb BD. Germ-line and somatic PTPN11 mutations in human
disease. Eur J Med Genet. 2005; 48: 81-96.
- Jongmans MC, van der Burgt I, Hoogerbrugge PM, et al. Cancer risk in
patients with Noonan syndrome carrying a PTPN11 mutation. Eur J
Hum Genet. 2011; 19: 870-4.
- Han T, Xiang DM, Sun W, et al. PTPN11/Shp2 overexpression enhances
liver cancer progression and predicts poor prognosis of patients.J Hepatol. 2015; 63: 651-60.
- Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as a tumor
suppressor in hepatocellular carcinogenesis. Cancer Cell. 2011; 19:
629-39.
- Jiang C, Hu F, Tai Y, et al. The tumor suppressor role of Src homology
phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J
Cancer Res Clin Oncol. 2012; 138:637-46.
- Grossmann KS, Rosário M, Birchmeier C, et al. The tyrosine phosphatase
Shp2 in development and cancer. Adv Cancer Res. 2010; 106:
53-89.
- Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate
the SHP-2 phosphatase in leukemogenesis. Blood. 2004; 103:
2325-31.
- Kogiso T, Tokushige K. Fontan-associated liver disease and
hepatocellular carcinoma in adults. Sci Rep. 2020; 10: 21742.